Literature DB >> 33057570

Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer.

Robert S Copeland-Halperin1, Mohammed Al-Sadawi2, Sujata Patil3,4, Jennifer E Liu1,4, Richard M Steingart1,4, Chau T Dang1,4, Anthony F Yu1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33057570      PMCID： PMC7563661          DOI： 10.1001/jamaoncol.2020.4749

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.

Authors:  Joerg Herrmann; Daniel Lenihan; Saro Armenian; Ana Barac; Anne Blaes; Daniela Cardinale; Joseph Carver; Susan Dent; Bonnie Ky; Alexander R Lyon; Teresa López-Fernández; Michael G Fradley; Sarju Ganatra; Giuseppe Curigliano; Joshua D Mitchell; Giorgio Minotti; Ninian N Lang; Jennifer E Liu; Tomas G Neilan; Anju Nohria; Rupal O'Quinn; Iskra Pusic; Charles Porter; Kerry L Reynolds; Kathryn J Ruddy; Paaladinesh Thavendiranathan; Peter Valent
Journal:  Eur Heart J       Date:  2022-01-31       Impact factor: 35.855

Review 2.  Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction.

Authors:  Irma Zhang; Ana Barac
Journal:  Curr Oncol Rep       Date:  2022-04-01       Impact factor: 5.945

Review 3.  Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.

Authors:  Susan F Dent; Amber Morse; Sarah Burnette; Avirup Guha; Heather Moore
Journal:  Curr Oncol Rep       Date:  2021-08-27       Impact factor: 5.075

Review 4.  [Evidence in minimally invasive oncological gastric surgery].

Authors:  Kaja Ludwig; Christian Barz; Uwe Scharlau
Journal:  Chirurg       Date:  2021-04       Impact factor: 0.955

5.  Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer.

Authors:  Sivisan Suntheralingam; Chun-Po Steve Fan; Oscar Calvillo-Argüelles; Husam Abdel-Qadir; Eitan Amir; Paaladinesh Thavendiranathan
Journal:  J Clin Med       Date:  2022-02-05       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.